ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach

The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahota, has resigned from the role at the association after the company breached the ABPI's Code of Practice.

Scales — Novo Nordisk ABPI Code Of Practice Breaches Involve Weight Loss Drug Saxenda • Source: Shutterstock

Pinder Sahota, UK manager of Novo Nordisk Pharma AG, has resigned as president of the Association of the British Pharmaceutical Industry, amid a process relating to breaches of the ABPI Code of Practice by the company. Such breaches can lead to a company’s expulsion or suspension from the association.

Sahota made the decision to step down “as he does not wish the ongoing process around a Novo Nordisk ABPI...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

09 Jun 2025

• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

06 Jun 2025

• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

06 Jun 2025

• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

05 Jun 2025

• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Pink Sheet Podcast: Prasad Staying Out Of Application Reviews, US FDA Proposed Budget Cuts

06 Jun 2025

• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss CBER Director Vinay Prasad’s expectation to stay out of routine application decisions, despite the agency’s top-down leadership approach, and the extent of proposed FDA budget cuts.